The global benign prostatic hyperplasia (BPH) treatment market size was valued at US$ 27.7 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5% from 2022 to 2032.
The global benign prostatic hyperplasia (BPH) treatment market is estimated to be worth US$ 47.17 Billion by the end of 2032. In 2021, the global benign prostatic hyperplasia treatment market revenue accounted for 24% of the global cancer treatment market. The growing preference for minimally invasive surgeries is expected to drive demand for BPH surgical treatment procedures in the coming decades.
For more insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4412?SP
The readability score of the Benign Prostatic Hyperplasia Market Demand report is good as it offers chapter-wise layout with each section divided into a smaller sections.
The report encompasses graphs and tables to show the entire assembling. Pictorial demonstration of the definite and estimated values of key segments is visually appealing to readers.
This Benign Prostatic Hyperplasia market outlook report explicates on vital dynamics such as the drivers, restraints and opportunities for key players and competitive analysis of Benign Prostatic Hyperplasia along with key stakeholders as well as emerging players associated with the manufacturing of product.
Competitive Landscape:
Key players in the Benign Prostatic Hyperplasia Treatment market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Manufacturers of BPH treatment devices and drugs are investing in research and development to develop innovative treatments that will provide optimal therapeutic options for people suffering from the disease. Some of the novel developments by key manufacturers are
- In January 2021, PHAREX Health Corporation introduced Pharex Tamsulosin for BPH treatment in collaboration with the Philippine Urological Association (PUA).
- UroLift launched the Advanced Tissue Control (ATC) System in 2020.
- Asahi Kasei Pharma received Chinese approval for Flivas in 2020.
- Alembic was granted FDA approval for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg in 2019.
Key Segments Profiled in the Benign Prostatic Hyperplasia Treatment Industry Survey:
· By Treatment :
- Drug Class
- Alpha Blockers
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Others
- Minimally-invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Robotic Surgeries
- Transurethral Microwave Thermotherapy (TUMT)
- Prostatic Urethral Lift
- Others
- Laser Therapy
- Others
· By End User :
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
- Others
· By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
For in-depth competitive analysis, Buy Now:
https://www.factmr.com/checkout/4412
Questionnaire answered in the Market outlook Report of Benign Prostatic Hyperplasia include:
- What is the key strategy deployed by large players to maximize Benign Prostatic Hyperplasia Market growth?
- What are the main challenges faced by players in the Benign Prostatic Hyperplasia market Demand?
- With the advent of technological advancement, how will the Benign Prostatic Hyperplasia market landscape change over the forecast period?
- What does player bring to the table which is unique as a strategy, and is easy to emulate for new investors in the Benign Prostatic Hyperplasia market size?
How will be insights and market estimations provided in the Fact.MR report on the Demand of Benign Prostatic Hyperplasia make a difference?
- The study takes a closer look at the major economic turmoil, with a focus on the recent COVID-19 pandemic disruptions
- The assessment of key growth dynamics highlights the attractiveness of new automation technologies and offers readers insight on the prospect of these during the forecast period
- The study tries to offer a balance perspective of the opportunities in mature and the most lackluster markets
- Provides scrutiny of the industry trends that have shaped recent government policies
- Provides an account of major breakthroughs in all segments that might change the course of the market considerably
- Provides an incisive analysis of socio-political milieu in which the key markets operate, and how will that influence the lucrativeness of the overall Benign Prostatic Hyperplasia Market
- Analyzes how collaborations and partnerships among players from different industries shape the key growth dynamics in the near future
- Evaluates the role of various stages of funding on new growth avenues in key regional markets
Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: [email protected]